Altheos, Inc. is an early stage biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs.
Altheos, Inc. completed $20MM series A financing in March 2010 led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital. The financing will be used primarily for the development of ATS907, a selective Rho-kinase inhibitor for topical treatment of glaucoma that Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of highly active compounds specifically for topical treatment for glaucoma.
Funding Rounds (2) - $32.5MUpdate
|Feb 9, 2012||Fierce Biotech - Altheos raises 12500000 in venture round|
|Apr 5, 2010||Fierce Biotech - Glaucoma drug focus inspires $20M A round for Altheos|
400 Oyster Point Boulevard
South San Francisco, CA 94080